Global investment firm Carlyle is reportedly preparing to divest up to a 10% stake in India-listed Piramal Pharma, according to a report by Moneycontrol, citing sources familiar with the matter.
The sale, expected to be executed via block trades, could generate proceeds of between INR26bn and INR27bn (approximately $305-315m). Neither Carlyle nor Piramal Pharma has commented publicly on the potential transaction.
As of the end of March 2025, Carlyle – through its affiliate CA Alchemy Investments – held an 18% interest in Piramal Pharma, exchange filings show. The firm initially acquired a 20% stake in the Mumbai-based pharmaceutical company in 2020 in a deal valued at around $490m.
The prospective partial exit comes amid broader activity across India’s healthcare and life sciences sector, where global private equity interest remains robust, supported by strong domestic demand and resilient fundamentals.
